Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study | Synapse
March 3, 2026Open Access
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study
Key Points
Improved efficacy observed with the combination of anti-LAG-3 and sintilimab in patients.
Significant findings included a notable progression-free survival of 10.5 months in treatment groups.
Observational analysis across multiple centers assessing phase II clinical trial data.
Findings highlight the potential for enhanced treatment strategies against advanced squamous non-small cell lung cancer.